


## Elubrixin

## Chemical Properties

CAS No. :	688763-64-6
Formula:	C <sub>17</sub> H <sub>17</sub> Cl <sub>2</sub> FN <sub>4</sub> O <sub>4</sub> S
Molecular Weight:	463.31
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Elubrixin (SB-656933) inhibits neutrophil CD11b upregulation (IC <sub>50</sub> of 260.7 nM) and shape change (IC <sub>50</sub> of 310.5 nM). Elubrixin can be used for inflammatory diseases such as inflammatory bowel disease and airway inflammation. Elubrixin is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.
Targets(IC <sub>50</sub> )	CXCR,IL Receptor,Interleukin
In vitro	Elubrixin inhibits neutrophil CD11b upregulation with an IC <sub>50</sub> of 260.7 nM and shapes change with an IC <sub>50</sub> of 310.5 nM. Elubrixin has an inhibitory effect on neutrophils in a dose-dependent manner[3].

## Solubility Information

Solubility	DMSO: 10 mg/mL (21.58 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1584 mL	10.7919 mL	21.5838 mL
5 mM	0.4317 mL	2.1584 mL	4.3168 mL
10 mM	0.2158 mL	1.0792 mL	2.1584 mL
50 mM	0.0432 mL	0.2158 mL	0.4317 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Lazaar AL, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. *Br J Clin Pharmacol*. 2011 Aug;72(2):282-93.

Nicholson GC, et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. *Pulm Pharmacol Ther*. 2007;20(1):52-9.

Mozaffari S, et al. Inflammatory bowel disease therapies discontinued between 2009 and 2014. *Expert Opin Investig Drugs*. 2015;24(7):949-56.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481